Effects of raloxifene on the renin-angiotensin-aldosterone system and blood pressure in hypertensive and normotensive osteoporotic postmenopausal women

Geriatrics & Gerontology International
Hiroyuki SuminoMasahiko Kurabayashi

Abstract

An increase in blood pressure after menopause has been documented. The renin-angiotensin-aldosterone system (RAAS) plays a central role in the regulation of blood pressure and in the pathophysiology of hypertension. This study investigated the effects of raloxifene, a selective estrogen receptor modulator, on components of the RAAS and blood pressure in hypertensive and normotensive osteoporotic postmenopausal women. A total of 41 hypertensive or normotensive postmenopausal women with osteoporosis or osteopenia were divided into four groups. Eleven hypertensive and eight normotensive women received raloxifene hydrochloride (60 mg/day) p.o. for 6 months, and 12 hypertensive and 10 normotensive women did not receive raloxifene hydrochloride for 6 months. In all of the hypertensive women, blood pressure had been controlled prior to the start of the study using a variety of antihypertensive drugs other than angiotensin-converting enzyme (ACE) inhibitors, angiotensin (Ang)II type 1 receptor antagonists or diuretics. Plasma renin activity (PRA), serum ACE activity, plasma AngI, AngII and aldosterone concentrations, and blood pressure were measured before and 6 months after the start of the study. No significant changes in PRA, ACE ac...Continue Reading

References

May 15, 1989·Clinica Chimica Acta; International Journal of Clinical Chemistry·T YamamotoO Takatori
Jun 19, 1986·The New England Journal of Medicine·R J ChetkowskiH L Judd
Dec 1, 1981·The Journal of Endocrinology·J StaessenA Amery
Apr 21, 1982·The American Journal of Cardiology·P LijnenA Amery
Aug 1, 1994·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·J A KanisN Khaltaev
Jul 27, 1999·The Journal of Steroid Biochemistry and Molecular Biology·H U BryantM Sato
Dec 11, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·G W de Valk-de RooC Netelenbos
Mar 30, 2000·American Journal of Obstetrics and Gynecology·W D ZomaK E Clark
Feb 12, 2002·The American Journal of Cardiology·Thomas Unger
Feb 20, 2002·JAMA : the Journal of the American Medical Association·Elizabeth Barrett-ConnorUNKNOWN MORE Investigators (Multiple Outcomes of Raloxifene Evaluation)
Sep 20, 2002·Journal of Atherosclerosis and Thrombosis·Yoshiya HataUNKNOWN Working Committee on JAS Guideline for Diagnosis and Treatment of Hyperlipidemias
Mar 29, 2003·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hiroyuki SuminoMasahiko Kurabayashi
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Jul 31, 2003·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hiroyuki SuminoMasahiko Kurabayashi
Jan 14, 2004·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shin-ichiro MiuraSadashiva S Karnik
Dec 13, 2005·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Mitsuhiro GotohMichihiko Takahashi
Jul 14, 2006·The New England Journal of Medicine·Elizabeth Barrett-ConnorUNKNOWN Raloxifene Use for The Heart (RUTH) Trial Investigators
Jul 26, 2006·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Giuseppe MorganteVincenzo De Leo
Mar 21, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Toshio OgiharaUNKNOWN Japanese Society of Hypertension Committee

❮ Previous
Next ❯

Citations

Oct 1, 2014·Menopause : the Journal of the North American Menopause Society·Zeinab IssaGhada El-Hajj Fuleihan
Jun 3, 2020·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Qingfen HuShumin Yang
Oct 1, 2020·BMC Endocrine Disorders·Flavio A Cadegiani
Jun 1, 2011·Basic & Clinical Pharmacology & Toxicology·Adriana Nunes MoraesGláucia Rodrigues Abreu
Nov 17, 2019·La Presse médicale·Theodora Bejan-Angoulvant, Jean-Francois Arnal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.